ArticleJournal of neuro-oncology2026
Tumor treating fields for newly diagnosed glioblastoma: a retrospective analysis.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Identification of a lncRNA prognostic signature reveals that SNAI3-AS1 cooperates with erastin to reshape macrophage polarization in glioma.Medical oncology (Northwood, London, England) · 2026Article
- Review
- Biomarkers for predicting immunotherapy response and resistance in glioblastoma.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionTumor Treating Fields (TTFields), as an emerging non-invasive therapeutic approach, has gradually demonstrated its potential as an adjuvant therapy in cancer treatment in recent years. Currently, TTFields has become an important adjunct to the standard treatment of glioblastoma (GBM). Real-world data on its clinical application, outcomes, and prognostic factors hold significant value for optimizing clinical practice. This study aims to evaluate the actual effectiveness of TTFields in treating GBM by providing clinical data and exploring potential clinical factors that may influence its efficacy.
methodsThis study is a retrospective cohort study that included 40 newly diagnosed glioblastoma (ndGBM) patients received TTFields treatment based on the Stupp regimen. Additionally, 48 ndGBM patients who did not receive TTFields treatment during the same period were selected as the control group through continuous sampling. Kaplan-Meier curves were employed to estimate the overall survival (OS) and progression-free survival (PFS) in both groups. To identify factors affecting these outcomes and the efficacy of TTFields, a Cox regression analysis was subsequently performed on various clinical variables.
resultsPatients receiving the TTFields demonstrated superior median PFS (12.0 months, 95%CI: 8.97-15.03) and OS (18.0 months, 95%CI: 13.65-22.35), versus 9.0 (95%CI: 7.06-10.94) and 12.0 (95%CI: 9.36-14.64) months in controls. Multivariate analysis showed that the extent of resection (P = 0.032, HR: 0.47, 95%CI: 0.24-0.94), the MGMT promoter methylation status (P = 0.024, HR: 0.51, 95%CI: 0.28-0.91) and whether accepted TTFields therapy (P = 0.022, HR: 0.50, 95%CI: 0.28-0.90) were independent prognostic factors affecting PFS. Additionally, patient compliance with TTFields therapy was significantly associated with their OS and PFS (OS: P = 0.004, HR: 0.12, 95%CI: 0.03-0.51; PFS: P = 0.007, HR: 0.24, 95%CI: 0.09-0.68). Further analysis revealed a certain relationship between the duration of TTFields therapy and survival. Comparative analysis revealed distinct survival outcomes based on treatment duration. The long-term (> 2 months) and short-term (≤ 2 months) TTFields groups had median OS of 21.0 (95%CI: 15.58-26.42) and 16.0 months (95%CI: 10.32-21.68) (P = 0.099), and median PFS of 20.0 (95%CI: 6.99-33.01) and 8.0 months (95%CI: 4.36-11.65) (P = 0.017), respectively, indicating a statistically significant PFS advantage for prolonged therapy.
conclusionsThe TTFields combined with Stupp regimen was associated with longer Survival outcome in patients with GBM. Additionally, higher patient compliance with TTFields treatment (≥ 0.81) and prolonged use of TTFields (> 2 months) are closely associated with improved prognosis.
Indexed as
Identifiers
41697534What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.